Aurinia Pharmaceuticals, Inc. (AUPH)
15.50
-0.18
(-1.12%)
USD |
NASDAQ |
Dec 09, 16:00
15.58
+0.08
(+0.48%)
After-Hours: 17:02
Aurinia Pharmaceuticals EPS Diluted (Quarterly): 0.232 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 1.432 |
| Oncolytics Biotech, Inc. | -0.1032 |
| Edesa Biotech, Inc. | -0.2491 |
| Lexaria Bioscience Corp. | -0.1378 |
| Xenon Pharmaceuticals, Inc. | -1.147 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 31.55M |
| Revenue (Quarterly) | 73.47M |
| Total Expenses (Quarterly) | 41.92M |
| Enterprise Value | 1.794B |
| Gross Profit Margin (Quarterly) | 88.87% |
| Profit Margin (Quarterly) | 42.95% |
| Earnings Yield | 3.62% |
| Operating Earnings Yield | 4.44% |
| Normalized Earnings Yield | 4.140 |